GLP-1 receptor agonists in inflammatory rheumatic diseases: immunometabolic impact, obesity, and therapeutic potential
DOI:
https://doi.org/10.62452/2xf01v27Keywords:
GLP-1 agonists, inflammatory rheumatic diseases, immunometabolismAbstract
Inflammatory rheumatic diseases (IRDs) are a major cause of disability worldwide and are characterized by persistent immune activation associated with chronic inflammation. In this context, the present study aimed to analyze the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in inflammatory rheumatic diseases, with particular emphasis on their immunometabolic effects and their potential benefits for patients with metabolic comorbidities, especially obesity. A literature review was conducted using scientific publications in English and Spanish. The evidence indicates that IRDs share common pathophysiological mechanisms, including loss of immune tolerance, autoantibody production, immune complex formation, and systemic inflammation. In addition, metabolic disorders such as obesity, type 2 diabetes mellitus, and dyslipidemia contribute to a chronic low-grade inflammatory state that exacerbates disease activity and worsens clinical outcomes. The reviewed studies suggest that GLP-1 receptor agonists exert anti-inflammatory and immunometabolic effects that may complement conventional therapies by improving metabolic control and reducing systemic inflammation. Although the available findings are promising, current evidence remains limited. Therefore, well-designed clinical studies with greater methodological rigor are needed to establish the efficacy and safety of GLP-1 receptor agonists as part of the comprehensive management of inflammatory rheumatic diseases.
Downloads
References
Ansari, S., Khoo, B., & Tan, T. (2024). Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology, 20, 447–459. https://doi.org/10.1038/s41574-024-00979-9
Battistoni, A., Piras, L., Tartaglia, N., Carrano, F. M., De Vitis, C., & Barbato, E. (2025). Glucagon-like peptide-1 receptor agonists and the endothelium: Molecular and clinical insights into cardiovascular protection. Frontiers in Medicine, 12, 1669685. https://doi.org/10.3389/fmed.2025.1669685
Beutler, L. R. (2026). GLP-1 physiology and pharmacology along the gut-brain axis. The Journal of Clinical Investigation, 136(2), e194744. https://doi.org/10.1172/JCI194744
Bilgin, E., Venerito, V., & Bogdanos, D. P. (2025). Glucagon-like peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. Autoimmunity Reviews, 24(9), 103864. https://doi.org/10.1016/j.autrev.2025.103864
Chamchoum, E., Katrib, N., Nassif, N., Ratel, Y., & Rida, M. A. (2025). Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases. World Journal of Experimental Medicine, 15(3), 107020. https://doi.org/10.5493/wjem.v15.i3.107020
Choi, H. M., Doss, H. M., & Kim, K. S. (2020). Multifaceted physiological roles of adiponectin in inflammation and diseases. International Journal of Molecular Sciences, 21(4), 1219. https://doi.org/10.3390/ijms21041219
Davison, A., Reimann, F., & Gribble, F. M. (2025). Molecular mechanisms of stimulus detection and secretion in enteroendocrine cells. Current Opinion in Neurobiology, 92, 103045. https://doi.org/10.1016/j.conb.2025.103045
Donniacuo, A., Mauro, A., Cardamone, C., Basile, A., Manzo, P., Dimitrov, J., Cammarota, A. L., Marzullo, L., Triggiani, M., Turco, M. C., De Marco, M., & Rosati, A. (2025). Comprehensive profiling of cytokines and growth factors: Pathogenic roles and clinical applications in autoimmune diseases. International Journal of Molecular Sciences, 26(18), 8921. https://doi.org/10.3390/ijms26188921
Drucker, D. J. (2025). GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery, 24, 631–650. https://doi.org/10.1038/s41573-025-01183-8
Engin, A. (2024). Endothelial dysfunction in obesity and therapeutic targets. En A. B. Engin & A. Engin (Eds.), Obesity and lipotoxicity (Advances in Experimental Medicine and Biology, Vol. 1460, pp. 489–538). Springer.
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., Akhtar, M., & Mahmmoud Fadelallah Eljack, M. (2025). Exploring the multifaceted roles of GLP-1 receptor agonists: A comprehensive review. Frontiers in Clinical Diabetes and Healthcare, 6, 1590530. https://doi.org/10.3389/fcdhc.2025.1590530
Hanif, M., Nagarajan, J. S., Murphy, R., Sah, S. P., Ye, S., Perl, A., & Taub, C. C. (2026). Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes. The American Journal of Medicine, 139(6), 769–781.e8. https://doi.org/10.1016/j.amjmed.2026.02.016
Jácome Aguilar, A. L., & Jácome Aguilar, E. N. (2026). Asociación entre psoriasis y síndrome metabólico: Implicaciones clínicas. Ciencia Y Educación, 7(2.2), 254 - 262. https://doi.org/10.5281/zenodo.18948517
Karacabeyli, D., & Lacaille, D. (2024). Glucagon-like peptide-1 receptor agonists in patients with inflammatory arthritis or psoriasis: A scoping review. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 30(1), 26–31. https://doi.org/10.1097/RHU.0000000000001949
López, M., & Gualillo, O. (2024). Rheumatic diseases and metabolism: Where centre and periphery meet. Nature Reviews Rheumatology, 20, 783–794. https://doi.org/10.1038/s41584-024-01178-6
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebkar, A., Chen, Z., Luo, S., Zheng, X., Weng, J., & Xu, S. (2021). GLP-1 receptor agonists (GLP-1RAs): Cardiovascular actions and therapeutic potential. International Journal of Biological Sciences, 17(8), 2050–2068. https://doi.org/10.7150/ijbs.59965
Martinis, E., Tonon, S., Colamatteo, A., La Cava, A., Matarese, G., & Pucillo, C. E. M. (2025). B cell immunometabolism in health and disease. Nature Immunology, 26(3), 366–377. https://doi.org/10.1038/s41590-025-02102-0
Patiño-Martínez, E., & Kaplan, M. J. (2025). Immunometabolism in systemic lupus erythematosus. Nature Reviews Rheumatology, 21(7), 377–395. https://doi.org/10.1038/s41584-025-01267-0
Pena, C., Subedi, B., Akbari, H., Lau, A., Rodriguez, F., & Tan, I. (2025). Impact of GLP-1 receptor agonists on major adverse cardiovascular events in ankylosing spondylitis: A retrospective cohort study. Annals of the Rheumatic Diseases, 84, 1289–1290. https://doi.org/10.1016/j.ard.2025.06.582
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020). Regulatory T cells and human disease. Annual Review of Immunology, 38, 541–566. https://doi.org/10.1146/annurev-immunol-042718-041717
Weyand, C. M., & Goronzy, J. J. (2021). The immunology of rheumatoid arthritis. Nature Immunology, 22(1), 10–18. https://doi.org/10.1038/s41590-020-00816-x
Yen, F.-S., Wang, S.-I., Hwu, C.-M., Huang, C.-W., Chang, R., Hsu, C.-C., & Wei, J. C.-C. (2025). Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Journal of Autoimmunity, 157, 103493. https://doi.org/10.1016/j.jaut.2025.103493
Yuseff, M.-I., Pierobon, P., Reversat, A., & Lennon-Duménil, A.-M. (2013). How B cells capture, process and present antigens: A crucial role for cell polarity. Nature Reviews Immunology, 13(7), 475–486. https://doi.org/10.1038/nri3469
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024). Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9, 234. https://doi.org/10.1038/s41392-024-01931-z
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Liliana Teruel-Leyva, Victorino Chicapa-Vicente, Ricardo Sebastian Mayorga-Miranda, Gary Raúl Vaca-González, Daniela Stefania Gallardo-Ruiz (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in Revista Metropolitana de Ciencias Aplicadas (REMCA), agree to the following terms:
1. Copyright
Authors retain unrestricted copyright to their work. Authors grant the journal the right of first publication. To this end, they assign the journal non-exclusive exploitation rights (reproduction, distribution, public communication, and transformation). Authors may enter into additional agreements for the non-exclusive distribution of the version of the work published in the journal, provided that acknowledgment of its initial publication in this journal is given.
© The authors.
2. License
The articles are published in the journal under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). The terms can be found at: https://creativecommons.org/licenses/by-nc-sa/4.0/deed.en
This license allows:
- Sharing: Copying and redistributing the material in any medium or format.
- Adapting: Remixing, transforming, and building upon the material.
Under the following terms:
- Attribution: You must give appropriate credit, provide a link to the license, and indicate if any changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses or sponsors your use.
- NonCommercial: You may not use the material for commercial purposes.
- ShareAlike: If you remix, transform, or build upon the material, you must distribute your creation under the same license as the original work.
There are no additional restrictions. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
